A5023725048- MicroRNA in disease regulation
- Epigenetics and DNA Methylation
- Cancer-related molecular mechanisms research
- Circular RNAs in diseases
- Cancer, Hypoxia, and Metabolism
- Cancer, Lipids, and Metabolism
- RNA modifications and cancer
- Histone Deacetylase Inhibitors Research
- Cancer-related gene regulation
- HER2/EGFR in Cancer Research
- Peptidase Inhibition and Analysis
- Renal and related cancers
- Childhood Cancer Survivors' Quality of Life
- Cancer Research and Treatment
- Cancer Treatment and Pharmacology
- Diet and metabolism studies
- Vascular Tumors and Angiosarcomas
- Cytokine Signaling Pathways and Interactions
- FOXO transcription factor regulation
- Tea Polyphenols and Effects
- Advanced Breast Cancer Therapies
- Metabolomics and Mass Spectrometry Studies
- Birth, Development, and Health
- Coffee research and impacts
- Radiopharmaceutical Chemistry and Applications
INCLIVA Health Research Institute
2020-2025
Biomedical Research Institute
2024
Weatherford College
2024
Instituto Português de Oncologia Francisco Gentil
2018-2020
Universidade do Porto
2018-2020
IPO Porto
2020
Despite advances in breast cancer treatment, it remains the leading cause of cancer-related death women worldwide. In this context, microRNAs have emerged as potential therapeutic targets but still present some limitations for vivo applications. Particularly, miR-200c-3p is a well-known tumor suppressor microRNA that inhibits progression and metastasis through downregulating ZEB1 ZEB2. Based on above, we describe design validation nanodevice using mesoporous silica nanoparticles delivery...
Abstract Esophageal squamous cell carcinoma (ESCC), the most frequent esophageal cancer (EC) subtype, entails dismal prognosis. Hypoxia, a common feature of advanced ESCC, is involved in resistance to radiotherapy (RT). RT response hypoxia might be modulated through epigenetic mechanisms, constituting novel targets improve patient outcome. Post-translational methylation histone can partially by lysine demethylases (KDMs), which specifically removes methyl groups certain residues. KDMs...
Background: Renal cell carcinoma (RCC) displays a glycolytic phenotype (Warburg effect). Increased lactate production, impacting on tumor biology and microenvironment modulation, has been implicated in epigenetic mechanisms’ regulation, leading to histone deacetylases inhibition. Thus, in-depth knowledge of lactate’s impact epigenome regulation highly tumors might allow for new therapeutic strategies. Herein, we investigated how extracellular affected sirtuin 1 activity, class III...
MicroRNAs have emerged as new diagnostic and therapeutic biomarkers for breast cancer. Herein, we analysed miR-99a-5p expression levels in primary tumours plasma of cancer patients to evaluate its usefulness a minimally invasive biomarker. MiR-99a-5p were determined by quantitative real-time PCR three independent cohorts patients: (I) Discovery cohort: tissues (n = 103) healthy 26); (II) Testing samples from 105 98 donors; (III) Validation 89 85 donors. Our results demonstrated that was...
Our results show the following:•Low miR-30b-5p expression was detected in breast tumor tissue compared with healthy tissue.•High circulating levels plasma were associated to cancer.•miR-30b-5p identify cancer of all subtypes and stages disease.•Circulating relate patients' burden.•Circulating is a potential non-invasive cost-effective diagnostic BC biomarker. BackgroundRecently, microRNAs have been demonstrated be biomarkers for diagnosis, prognosis assessment or prediction response...
Sirtuins are emerging players in cancer biology and other age-related disorders, their putative role bladder (BlCa) remains elusive. Further understanding of disease may allow for generation more effective pathway-based biomarkers targeted therapies. Herein, we aimed to illuminate the sirtuins’ family BlCa evaluate potential as therapeutic targets. SIRT1-7 transcripts protein levels were evaluated a series primary normal mucosa tissues. SIRT7 knockdown was performed through lentiviral...
Abstract Despite progress in breast cancer treatment, a significant portion of patients still relapse because drug resistance. The involvement microRNAs progression and chemotherapy response is well established. Therefore, this study aimed to elucidate the dysregulation microRNA-449 family (specifically, microRNA-449a, microRNA-449b-5p, microRNA-449c-5p) its impact on resistance doxorubicin, commonly used chemotherapeutic for treatment triple-negative cancer. We found that downregulated...
Abstract The anti-HER2 monoclonal antibody trastuzumab and new derivative formulations are the standard treatment for HER2-positive breast cancer. However, after 1 to 5 years of treatment, some patients acquire resistance therapy, leading relapse. microRNA-449 family members were downregulated in cancer cell lines low levels associated with patients’ worse prognosis. Moreover, trastuzumab-resistant showed lower microRNAs-449 higher Fatty Acid Synthase (FASN) expression, compared sensitive...
The early diagnosis of breast cancer is essential to improve patients’ survival rate. In this context, microRNAs have been described as potential diagnostic biomarkers for cancer. Particularly, circulating a strong value non-invasive biomarkers. Herein, we assessed the microRNA signature based on miR-30b-5p and miR-99a-5p levels in plasma biomarker This two-microRNA was constructed by Principal Component Analysis its prognostic discovery cohort blindly validated second from an independent...
Due to the lack of specific targets, cytotoxic chemotherapy still represents common standard treatment for triple-negative breast patients. Despite harmful effect on tumor cells, there is evidence that could modulate microenvironment in a way favoring propagation tumor. In addition, lymphangiogenesis process and its factors be involved this counter-therapeutic event. our study, we have evaluated expression main lymphangiogenic receptor VEGFR3 two cancer vitro models, resistant or not...
Background: trastuzumab is considered the standard of care for human epidermal growth factor receptor-2 (HER-2+) breast cancer patients. Regardless benefits its use, many early-stage patients eventually recur, and usually, disease progresses within a year. Since about half HER-2+ do not respond to trastuzumab, new biomarkers prognosis prediction are warranted allow better patient stratification. Annexin A1 (ANXA1) was previously reported contribute resistance through AKT activation. An...
Treatment for the HER2+ breast cancer subtype is still unsatisfactory, despite breakthroughs in research. The discovery of various new molecular mechanisms transcription factors may help to make treatment regimens more effective. factor SALL4 has been related aggressiveness and resistance therapy cancer. Its involvement signaling pathways are unknown subtype. In this study, we have evaluated implication through its expression patients' samples gain loss function cell lines. We found higher...
<title>Abstract</title> Despite progress in the breast cancer treatment, a significant portion of patients still relapse as consequence drug resistance. The involvement microRNAs progression and chemotherapy response is well established. Therefore, this study aimed to elucidate dysregulation microRNA-449 family (specifically, microRNA-449a, microRNA-449b-5p, microRNA-449c-5p) its impact on resistance commonly used chemotherapeutic doxorubicin triple-negative cancer. We found that...
1083 Background: Triple-negative breast cancer (TNBC) is an aggressive (BC) subtype comprising approximately 15% of BC. Conventional cytotoxic chemotherapies continue to be the mainstay for treatment this BC, which lacks targetable markers. In context, microRNAs have been described important role. The aim work was elucidate function miR-503-5p in doxorubicin resistance TNBC. Methods: expression evaluated TNBC cell line with acquired (MDA-MB-231R) and its parental (MDA-MB-231), by qRT-PCR....